Abstract
Escherichia coli is an important cause of bloodstream infections (BSI), which is of concern given its high mortality and increasing worldwide prevalence. Finding bacterial genetic variants that might contribute to patient death is of interest to better understand its mechanism and implement diagnostic methods that specifically look for those factors. E. coli samples isolated from patients with BSI are an ideal dataset to systematically search for those variants, as long as the influence of host factors such as comorbidities are taken into account. Here we performed a genome-wide association study (GWAS) using data from 910 patients with E. coli BSI from hospitals in Paris, France; we looked for associations between bacterial genetic variants and three patient outcomes (death at 28 days, septic shock and admission to intensive care unit), as well as two portals of entry (urinary and digestive tract), using various clinical variables from each patient to account for host factors. We did not find any associations between genetic variants and patient outcomes, potentially confirming the strong influence of host factors in influencing the course of BSI; we however found a strong association between the papGII/papGIII operon and entrance of E. coli through the urinary tract, which demonstrates the power of bacterial GWAS even when applied to actual clinical data. Despite the lack of associations between E. coli genetic variants and patient outcomes, we estimate that increasing the sample size by one order of magnitude could lead to the discovery of some putative causal variants. The adoption of bacterial genome sequencing of clinical isolates might eventually lead to the elucidation of the mechanisms behind BSI progression and the development of sequence-based diagnostics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially funded by a Translational Research Grant from the Agence Nationale de la Recherche (ANR), Ministry of Higher Education and Research, France 2015 (grant n ANR-15-CE-17-0019-01). ED was partially supported by the "Fondation pour la Recherche Medicale" (Equipe FRM 2016, grant number DEQ20161136698). GR was supported by a "Poste d'accueil" funded by the "Assistance Publique-Hopitaux de Paris" (AP-HP) and the "Commissariat a' l'energie atomique et aux energies alternatives" (CEA) personal grant for his PhD. MG was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2155 - project number 390874280.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Both multicenter clinical trials were approved by ethic committees. The Colibafi study was approved by the French Comite' de Protection des Personnes of Hopital Saint-Louis, Paris, France (approval #2004-06, June 2004). The Septicoli study was approved by the French Comite' de Protection des Personnes Ile de France n IV (IRB 00003835, March 2016) and was registered on clinical trials in September 2016 (ClinicalTrials.gov Identifier: NCT02890901). Because of their non-interventional nature, only an oral consent from patients was requested under French law. Both studies conformed to the principles of the Helsinki declaration.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* The names of the collaborators are listed in the Acknowledgement section.
Data Availability
All data produced in the present work are contained in the manuscript and are available in public repositories such as ENA and github
https://github.com/microbial-pangenomes-lab/2021_ecoli_pathogenicity
